The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients
In this MEDtalk, Camille Hamm discusses a study that focused on interclass switching within the IL-23 class of biologics for the treatment of psoriasis. The study specifically looked at patients who had failed to respond to the drug guselkumab and were subsequently switched to risankizumab to evaluate the effectiveness of this switch.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
